MONTE ROSA THERAPEUTICS INC (GLUE)

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 133 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Company Info

MONTE ROSA THERAPEUTICS INC

321 Harrison Avenue, Suite 900

Boston MASSACHUSETTS

P: 16179492643

CEO: Markus Warmuth

Employees: 133

Website: https://www.monterosatx.com/